Literature DB >> 12854268

[Sentinel lymph node biopsy in patients with cutaneous malignant melanoma].

Dorte Gad1, Pia Sjøgren.   

Abstract

INTRODUCTION: In the Department of Plastic Surgery of Odense University Hospital patients having cutaneous melanoma from 1 to 4 mm underwent sentinel lymph node (SLN) biopsy. The aim of this study was to evaluate results and complications.
MATERIAL AND METHODS: During the first three years one hundred and sixteen patients underwent SLN biopsy, one patient was excluded from the study. All patients were operated in general anaesthesia and followed according to recommendations of the Danish Melanoma Group.
RESULTS: Median follow-up was 16 months. 76% had negative SLN and 24% had positive SLN. No significant difference was recorded in median thickness in the two groups. In two patients SLN were false negative; in both patients the primary melanoma was located in the face. The complication rate was 8.5%. DISCUSSION: We conclude that SLN biopsy is a reliable method in staging the regional lymph nodes and determining the need of elective lymphadenectomy and that our results match the ones of international standard.

Entities:  

Mesh:

Year:  2003        PMID: 12854268

Source DB:  PubMed          Journal:  Ugeskr Laeger        ISSN: 0041-5782


  2 in total

1.  Prevention of an additional surgery for regional lymphadenectomy in melanoma: rapid intraoperative immunostaining of sentinel lymph node imprint smears.

Authors:  Vinod B Shidham; Richard Komorowski; Marcelle Neuberg; Alonzo Walker; Bruce H Campbell; Chung-Che Chang; William W Dzwierzynski
Journal:  Diagn Pathol       Date:  2006-09-25       Impact factor: 2.644

2.  Optimization of an immunostaining protocol for the rapid intraoperative evaluation of melanoma sentinel lymph node imprint smears with the 'MCW melanoma cocktail'

Authors:  Vinod B Shidham; Richard Komorowski; Virgilia Macias; Sushma Kaul; Glen Dawson; William W Dzwierzynski
Journal:  Cytojournal       Date:  2004-08-06       Impact factor: 2.091

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.